Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19
Mather et al.,
Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19,
American Journal of Gastroenterology, doi:10.14309/ajg.0000000000000832
PSM retrospective 878 hospitalized patients in the USA, 83 with existing famotidine use, showing significantly lower mortality with treatment.
risk of death, 61.4% lower, HR 0.39, p = 0.004, treatment 83, control 689, propensity score matching, Cox proportional hazards.
|
risk of death/intubation, 50.5% lower, HR 0.49, p = 0.003, treatment 83, control 689, propensity score matching, Cox proportional hazards.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Mather et al., 26 Aug 2020, retrospective, USA, peer-reviewed, 3 authors.
Abstract: Impact of Famotidine Use on Clinical Outcomes of
Hospitalized Patients With COVID-19
Jeffrey F. Mather, MS1, Richard L. Seip, PhD1 and Raymond G. McKay, MD1
INTRODUCTION: To compare outcomes in patients hospitalized with coronavirus (COVID-19) receiving famotidine
therapy with those not receiving famotidine.
METHODS:
Retrospective, propensity-matched observational study of consecutive COVID-19–positive patients
between February 24, 2020, and May 13, 2020.
RESULTS:
Of 878 patients in the analysis, 83 (9.5%) received famotidine. In comparison to patients not treated
with famotidine, patients treated with famotidine were younger (63.5 6 15.0 vs 67.5 6 15.8 years, P 5
0.021), but did not differ with respect to baseline demographics or preexisting comorbidities. Use of
famotidine was associated with a decreased risk of in-hospital mortality (odds ratio 0.37, 95%
confidence interval 0.16–0.86, P 5 0.021) and combined death or intubation (odds ratio 0.47, 95%
confidence interval 0.23–0.96, P 5 0.040). Propensity score matching to adjust for age difference
between groups did not alter the effect on either outcome. In addition, patients receiving famotidine
displayed lower levels of serum markers for severe disease including lower median peak C-reactive
protein levels (9.4 vs 12.7 mg/dL, P 5 0.002), lower median procalcitonin levels (0.16 vs 0.30 ng/mL,
P 5 0.004), and a nonsignificant trend to lower median mean ferritin levels (797.5 vs 964.0 ng/mL,
P 5 0.076). Logistic regression analysis demonstrated that famotidine was an independent predictor of
both lower mortality and combined death/intubation, whereas older age, body mass index >30 kg/m2,
chronic kidney disease, National Early Warning Score, and higher neutrophil-lymphocyte ratio were all
predictors of both adverse outcomes.
DISCUSSION:
Famotidine use in hospitalized patients with COVID-19 is associated with a lower risk of mortality, lower
risk of combined outcome of mortality and intubation, and lower levels of serum markers for severe
disease in hospitalized patients with COVID-19.
Am J Gastroenterol 2020;00:1–7. https://doi.org/10.14309/ajg.0000000000000832
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit